TradingView
AlenCiken
٣ شباط فبراير ٢٠١٩ ٢١:٥١
Marinus Announces Successful Clinical Trial Results
NASDAQ:MRNS
Marinus Pharmaceuticals, Inc.
NASDAQ
الوصف
⋅
٣ شباط فبراير ٢٠١٩ ٢١:٥١
top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial.
globenewswire.com/news-release/2017/09/11/1117414/0/en/Marinus-Announces-Successful-Clinical-Trial-Results-and-Declares-CDKL5-Disorder-Its-Lead-Pediatric-Orphan-Epilepsy-Program-for-Ganaxolone.html
Trend Analysis
Chart Patterns
Technical Indicators
المزيد